Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Biolase Inc (NASDAQ: BIOL) was $0.15 for the day, down -2.22% from the previous closing price of $0.15. In other words, the price has decreased by -$2.22 from its previous closing price. On the day, 0.71 million shares were traded. BIOL stock price reached its highest trading level at $0.1498 during the session, while it also had its lowest trading level at $0.1421.
Ratios:
Our analysis of BIOL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.68 and its Current Ratio is at 1.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, The Benchmark Company on June 19, 2019, initiated with a Speculative Buy rating and assigned the stock a target price of $2.
On April 25, 2017, Singular Research started tracking the stock assigning a Buy rating and target price of $2.50.
WallachBeth Downgraded its Buy to Hold on May 13, 2014, whereas the target price for the stock was revised from $4 to $2.50.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIOL now has a Market Capitalization of 4825576 and an Enterprise Value of 16063028. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.10. Its current Enterprise Value per Revenue stands at 0.327 whereas that against EBITDA is -1.152.
Stock Price History:
The Beta on a monthly basis for BIOL is 0.69, which has changed by -0.99285716 over the last 52 weeks, in comparison to a change of 0.22379243 over the same period for the S&P500. Over the past 52 weeks, BIOL has reached a high of $32.09, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is -4.28%, while the 200-Day Moving Average is calculated to be -91.98%.
Shares Statistics:
BIOL traded an average of 5.82M shares per day over the past three months and 768180 shares per day over the past ten days. A total of 33.26M shares are outstanding, with a floating share count of 31.91M. Insiders hold about 4.05% of the company’s shares, while institutions hold 4.44% stake in the company. Shares short for BIOL as of 1713139200 were 592678 with a Short Ratio of 0.10, compared to 1710460800 on 288865. Therefore, it implies a Short% of Shares Outstanding of 592678 and a Short% of Float of 1.78.
Earnings Estimates
The dynamic stock of Biolase Inc (BIOL) is currently being evaluated by a team of 2.0 analysts, each contributing to its current rating.On average, analysts expect EPS of -$0.17 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.21, while EPS last year was -$18. The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.02 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.24 and -$0.4 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is -$0.11, with 2.0 analysts recommending between -$0.09 and -$0.13.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $10.49M to a low estimate of $9.7M. As of the current estimate, Biolase Inc’s year-ago sales were $10.47MFor the next quarter, 3 analysts are estimating revenue of $14.09M. There is a high estimate of $14.3M for the next quarter, whereas the lowest estimate is $13.79M.
A total of 3 analysts have provided revenue estimates for BIOL’s current fiscal year. The highest revenue estimate was $52M, while the lowest revenue estimate was $51M, resulting in an average revenue estimate of $51.5M. In the same quarter a year ago, actual revenue was $49.16MBased on 3 analysts’ estimates, the company’s revenue will be $55.5M in the next fiscal year. The high estimate is $57.21M and the low estimate is $53.6M.
